MA44763A - Compositions pharmaceutiques et régimes posologiques destinés à une utilisation clinique d'anticorps anti-antigène 2 de cellules dendritiques du sang - Google Patents

Compositions pharmaceutiques et régimes posologiques destinés à une utilisation clinique d'anticorps anti-antigène 2 de cellules dendritiques du sang

Info

Publication number
MA44763A
MA44763A MA044763A MA44763A MA44763A MA 44763 A MA44763 A MA 44763A MA 044763 A MA044763 A MA 044763A MA 44763 A MA44763 A MA 44763A MA 44763 A MA44763 A MA 44763A
Authority
MA
Morocco
Prior art keywords
antigen
antibodies
intended
pharmaceutical compositions
dendritic cell
Prior art date
Application number
MA044763A
Other languages
English (en)
Inventor
David Dai
Mark R H Krebs
David Martin
Dania Rabah
Shantanu Sule
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MA44763A publication Critical patent/MA44763A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA044763A 2016-04-28 2017-04-27 Compositions pharmaceutiques et régimes posologiques destinés à une utilisation clinique d'anticorps anti-antigène 2 de cellules dendritiques du sang MA44763A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662328959P 2016-04-28 2016-04-28

Publications (1)

Publication Number Publication Date
MA44763A true MA44763A (fr) 2019-03-06

Family

ID=58672794

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044763A MA44763A (fr) 2016-04-28 2017-04-27 Compositions pharmaceutiques et régimes posologiques destinés à une utilisation clinique d'anticorps anti-antigène 2 de cellules dendritiques du sang

Country Status (14)

Country Link
US (2) US20190284281A1 (fr)
EP (1) EP3448425A1 (fr)
JP (3) JP7045327B2 (fr)
KR (5) KR102366547B1 (fr)
CN (2) CN116850282A (fr)
AU (2) AU2017258191B2 (fr)
CA (1) CA3022116A1 (fr)
CO (1) CO2018012506A2 (fr)
EA (1) EA201892443A1 (fr)
IL (2) IL262514B2 (fr)
MA (1) MA44763A (fr)
MX (3) MX2018012945A (fr)
PH (1) PH12018502278A1 (fr)
WO (1) WO2017189827A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA49962A (fr) * 2017-08-22 2020-07-01 Biogen Ma Inc Procédés de purification d'anticorps présentant des agrégats réduits à poids moléculaire élevé
EP3823594B1 (fr) 2018-07-19 2025-02-05 Ichnos Sciences S.A. Formulation d'anticorps liquide
KR200494676Y1 (ko) 2020-08-04 2021-12-01 (주) 티나인 버튼식 헤어 염색기
AU2021391803A1 (en) * 2020-12-03 2023-07-06 Biogen Ma Inc. Methods of treating cutaneous lupus erythematosus and systemic lupus erythematosus
KR20230022786A (ko) 2021-08-09 2023-02-16 주식회사 인벤테라제약 생체 내 주입 후 대식세포에 의해 탐식 및/또는 대사분해되지 않은 상태로 신장을 통해 소변으로 배출되는 나노 구조물
TW202400652A (zh) * 2022-05-25 2024-01-01 大陸商映恩生物製藥（蘇州）有限公司 抗ｂｄｃａ２抗體及其用途
IL321721A (en) * 2022-12-28 2025-08-01 Duality Biologics Shanghai Co Ltd Antidote conjugation against BDCA2 and its use
AU2024348487A1 (en) * 2023-09-28 2026-04-23 Nanjing Leads Biolabs Co., Ltd. Bdca2 monoclonal antibody, fusion protein composed of same and taci, and method and use therefor
WO2026008012A1 (fr) * 2024-07-04 2026-01-08 杭州博之锐生物制药有限公司 Anticorps anti-bdca2 et son utilisation
CN118638234B (zh) * 2024-07-04 2025-10-14 杭州博之锐生物制药有限公司 抗bdca2抗体及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004229335C1 (en) * 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
PT2928923T (pt) 2012-12-10 2020-03-27 Biogen Ma Inc Anticorpos antígenos 2 de células dendríticas anti-sangue e os seus usos

Also Published As

Publication number Publication date
AU2017258191B2 (en) 2024-06-13
JP2019520316A (ja) 2019-07-18
IL262514B1 (en) 2025-08-01
CA3022116A1 (fr) 2017-11-02
NZ747504A (en) 2025-08-29
MX2018012945A (es) 2019-03-06
EA201892443A1 (ru) 2019-04-30
KR20240033168A (ko) 2024-03-12
AU2024203240A1 (en) 2024-06-13
JP2024038308A (ja) 2024-03-19
CN116850282A (zh) 2023-10-10
KR20240159012A (ko) 2024-11-05
KR20250088784A (ko) 2025-06-17
IL262514A (en) 2018-12-31
WO2017189827A1 (fr) 2017-11-02
BR112018072125A2 (pt) 2019-03-19
AU2017258191A1 (en) 2018-11-15
PH12018502278A1 (en) 2019-09-09
US20190284281A1 (en) 2019-09-19
KR20190002563A (ko) 2019-01-08
MX2023008075A (es) 2023-07-18
NZ787392A (en) 2025-08-29
CN109475623A (zh) 2019-03-15
CO2018012506A2 (es) 2018-12-14
JP2022084782A (ja) 2022-06-07
IL321561A (en) 2025-08-01
JP7045327B2 (ja) 2022-03-31
US20250289895A1 (en) 2025-09-18
MX2025000037A (es) 2025-02-10
EP3448425A1 (fr) 2019-03-06
CN109475623B (zh) 2023-05-26
KR20220028150A (ko) 2022-03-08
IL262514B2 (en) 2025-12-01
KR102366547B1 (ko) 2022-02-23

Similar Documents

Publication Publication Date Title
EP3840730A4 (fr) Compositions pour l'administration d'agents thérapeutiques et leurs méthodes d'utilisation et leurs procédés de préparation
EP3630145A4 (fr) Compositions pharmaceutiques comprenant du cannabidiol et du bêta-caryophyllène et leurs procédés d'utilisation
EP3716945A4 (fr) Formes pharmaceutiques liquides, procédés de préparation et utilisation
IL321561A (en) Pharmaceutical formulations and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies
EP3528823A4 (fr) Déplacement latéral déterministe dans la préparation de cellules et de compositions à usages thérapeutiques
MA51796A (fr) Procédés et compositions pour l'administration de protéines thérapeutiques
EP3731868A4 (fr) Anticorps anti-tigit et leur utilisation comme agents thérapeutiques et diagnostiques
EP3645742A4 (fr) Anticorps anti-ror1 et leurs procédés de préparation et d'utilisation
MA45280A (fr) Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
EP2874642A4 (fr) Protéines et peptides anti-inflammatoires et leurs procédés de préparation et d'utilisation
EP3400013A4 (fr) Anticorps spécifiques pour la cadhérine-17 et cellules cytotoxiques pour le traitement du cancer
EP3897564A4 (fr) Agents de comblement tissulaire à base de soie-acide hyaluronique et leurs procédés de préparation et d'utilisation
EP3626239A4 (fr) Utilisation d'un inhibiteur d'ezh2 combiné à un inhibiteur de btk dans la préparation d'un médicament pour le traitement d'une tumeur
EP3380525A4 (fr) Formulations pharmaceutiques et leurs procédés d'utilisation
MA55090A (fr) Anticorps capable de se lier à la calréticuline mutante tronquée, et médicament de diagnostic, prophylactique ou thérapeutique pour néoplasmes myéloprolifératifs
EP3699192A4 (fr) Anticorps anti-cd3 et composition pharmaceutique destinée au traitement du cancer, contenant ledit anticorps
EP3672587A4 (fr) Compositions pharmaceutiques destinées au traitement d'affections ophtalmiques
MA41326A (fr) Formulations pharmaceutiques comprenant du cangrelor de haute pureté et leurs procédés de préparation et d'utilisation
MA55033A (fr) Formulation d'anticorps thérapeutique
EP3418305A4 (fr) Procédés d'expression et de préparation de protéine hybride d'anticorps bispécifique bivalent
EP3523333A4 (fr) Anticorps anti-ceacam6 et leurs procédés d'utilisation
EP3664797A4 (fr) Ligands de nr4a1, compositions pharmaceutiques et procédés d'utilisation associés
EP3362096A4 (fr) Composition de traitement ophtalmique et véhicule pour l'administration de substances pharmaceutiques ou d'agents thérapeutiques
EP4079761A4 (fr) Conjugué anticorps anti-cea-analogue d'exatécan et utilisation pharmaceutique de celui-ci